Royalty Report: Drugs, Arthritis, Disease – Collection: 245716

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Arthritis
  • Disease
  • Therapeutic
  • Cancer
  • Drug Discovery
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245716

License Grant
The Swiss Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
The nti-IL6R antibodies marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. The Licensee intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases.
Field of Use
Field means any and all uses including all therapeutic uses.  Licensed IP includes the nti-IL6R antibodies for a range of inflammatory conditions including rheumatoid arthritis.

Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (“BMS”), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.

IPSCIO Record ID: 245715

License Grant
The Swiss Licensor grants the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
NI-040 means the CD3 receptor monoclonal antibody Licensed Product, also known as foralumab and used in the treatment of inflammatory, auto-immune disorders, and cancer.

Targeting the CD3 receptor is a well-validated approach to modulating T-cell response and achieving immunosuppression. Foralumab is a phase II asset with potential application in a wide range of autoimmune and inflammatory diseases, such as multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

Field of Use
Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company, along with any associated know-how, biologic materials, clinical data or other technology relating to CD3 receptor monoclonal antibodies and their use in order to research, develop and commercialize products and services.

The Licensee will develop antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer using  CD3 receptor monoclonal antibodies.

IPSCIO Record ID: 289246

License Grant
Licensor grants the Chinese Licensee an exclusive, non-transferable, perpetual license in the field of Therapeutic usage in order to develop and conduct clinical trials to achieve Chinese FDA (SFDA) approval of the rabbit anti-TNFalpha monoclonal antibody compounds. Under these rights, Licensor grants both the manufacturing and distribution rights of anti-TNFalpha monoclonal antibody therapeutics covered under the intellectual properties rights owned by Licensor.
License Property
Licensor utilizes a proprietary and patented technology in the development and production of Rabbit Monoclonal Antibodies (RabMAb technology).

Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.

Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.

Field of Use
The field is for commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents.  Anti-TNFalpha therapies are effective in treating Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylis and Crohns diseases.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.